CytoAgents Details COVID-19 Trial on Business as Usual

Get a front row seat today at noon with CytoAgents CEO Teresa Whalen as she discusses the company's clinical trials for GP1681 -- Treatment of COVID-19 Cytokine Storm. As the CEO of CytoAgents, Teresa leads a team of world-renowned clinical drug development experts and scientific advisory board members who are at the forefront of groundbreaking solutions to combat persistent and potentially deadly strains of Influenza, COVID19 and other viruses. CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of COVID-19, Influenza and other viral infectious diseases. Using a novel, host-directed approach, CytoAgents targets the underlying cause of life-threatening symptoms associated with COVID-19, Influenza and Cytokine Releasing Syndrome by modulating the natural immune response to the disease. Discover how CytoAgents is committed to developing first-in-class, best-in-class products that meet a major medical need now and into the future.